Aim PROCLAIM, a phase III trial of patients with nonsquamous non–small cell lung cancer
comparing concurrent pemetrexed‐cisplatin and thoracic radiation therapy followed by …

Background and purpose To investigate associations of early post-treatment 18
Fluorodeoxyglucose-positron-emission-tomography (FDG-PET)-scans with local (LF) …

Purpose Approximately 20 to 40% of patients with surgically resected stage I non-small cell
lung cancer (NSCLC) will develop recurrent disease. Positron emission tomography (PET) …

Aim: Impact of elective nodal irradiation (ENI) on hilar/mediastinal control rates and survival
outcomes of stage III non-small-cell lung cancer (NSCLC) patients undergoing definitive …

Purpose To evaluate low dose non-enhanced CT and standard dose contrast-enhanced CT
in combined PET/CT protocols for staging and therapy planning of non-small cell lung …

Background and objective: The introduction of 18F‐FDG PET/CT has enhanced the
diagnostic accuracy of nodal staging for non‐small cell lung cancer (NSCLC). We analysed …

Background This study evaluated the clinical significance of maximum standardized uptake
value (SUVmax) on positron emission tomography (PET) in patients with subcentimeter non …

Objective: We sought to assess the clinical implication and prognostic significance of
maximum standardised uptake value (SUVmax) of primary non-small cell lung cancer …

Computed tomography (CT), 18 F-fluoro-2-deoxy-d-glucose positron emission
tomography/computed tomography (FDG-PET/CT), magnetic resonance (MR) imaging, and …

Introduction We investigated whether adding computed tomography (CT) and/or 18 F-
fluorodeoxyglucose (18 F-FDG) PET radiomics features to conventional prognostic factors …